Raman spectroscopic sensing of carbonate intercalation in breast microcalcifications at stereotactic biopsy

• Main Authors: Sathyavathi, R. (Author), Saha, Anushree (Author), Soares, Jaqueline S. (Author), Spegazzini, Nicolas (Contributor), McGee, Sasha (Author), Fitzmaurice, Maryann (Author), Barman, Ishan (Author), Dasari, Ramachandra Rao (Contributor)
• Other Authors: Massachusetts Institute of Technology. Department of Chemistry (Contributor), Massachusetts Institute of Technology. Laser Biomedical Research Center (Contributor), Massachusetts Institute of Technology. Spectroscopy Laboratory (Contributor)
• Format: Article
• Language: English
• Published: Nature Publishing Group, 2015-06-09T15:16:31Z.
• Subjects: Article
• Online Access: Get fulltext

Microcalcifications are an early mammographic sign of breast cancer and frequent target for stereotactic biopsy. Despite their indisputable value, microcalcifications, particularly of the type II variety that are comprised of calcium hydroxyapatite deposits, remain one of the least understood disease markers. Here we employed Raman spectroscopy to elucidate the relationship between pathogenicity of breast lesions in fresh biopsy cores and composition of type II microcalcifications. Using a chemometric model of chemical-morphological constituents, acquired Raman spectra were translated to characterize chemical makeup of the lesions. We find that increase in carbonate intercalation in the hydroxyapatite lattice can be reliably employed to differentiate benign from malignant lesions, with algorithms based only on carbonate and cytoplasmic protein content exhibiting excellent negative predictive value (93-98%). Our findings highlight the importance of calcium carbonate, an underrated constituent of microcalcifications, as a spectroscopic marker in breast pathology evaluation and pave the way for improved biopsy guidance.
National Institute for Biomedical Imaging and Bioengineering (U.S.) (9P41EB015871-27A1)
Johns Hopkins University. Whiting School of Engineering
National Cancer Institute (U.S.) (R01-CA140288)